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Abstract
Purpose Readers need to be informed about potential pitfalls of [68Ga]Ga-PSMA-11 PET interpretation.
Methods Here we report [68Ga]Ga-PSMA-11 PET findings discordant with the histopathology/composite reference standard in a
recently published prospective trial on 635 patients with biochemically recurrent prostate cancer.
Results Consensus reads were false positive in 20 regions of 17/217 (8%) patients with lesion validation. Majority of the false
positive interpretations (13 of 20, 65%) occurred in the context of suspected prostate (bed) relapse (T) after radiotherapy (n = 11);
other false positive findings were noted for prostate bed post prostatectomy (T, n = 2), pelvic nodes (N, n = 2), or extra pelvic
lesions (M, n = 5). Major sources of false positive findings were PSMA-expressing residual adenocarcinoma with marked post-
radiotherapy treatment effect. False negative interpretation occurred in 8 regions of 6/79 (8%) patients with histopathology
validation, including prostate (bed) (n = 5), pelvic nodes (n = 1), and extra pelvic lesions (n = 2). Lesions were missed mostly
due to small metastases or adjacent bladder/urine uptake.
Conclusion [68Ga]Ga-PSMA-11 PET at biochemical recurrence resulted in less than 10% false positive interpretations. Post-
radiotherapy prostate uptake was a major source of [68Ga]Ga-PSMA-11 PET false positivity. In few cases, PET correctly detects
residual PSMA expression post-radiotherapy, originating however from treated, benign tissue or potentially indolent tumor remnants.
Trial registration number ClinicalTrials.gov Identifiers: NCT02940262 and NCT03353740.
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Introduction
Positron-emission-tomography (PET) using [68Ga]Gallium-la-
beled ligands of the prostate-specific membrane antigen
(PSMA) localizes recurrent prostate cancer with high accuracy
and significant impact on management as demonstrated in sev-
eral retrospective reports and a recent prospective study [1–4].
At low serum PSA levels, detection rate and reproducibility are
superior compared with approved 18F-fluciclovine PET [5].
Consequently, clinical [68Ga]Ga-PSMA-11 PET application
has expanded rapidly, and more recently prospective PET-
guided interventional trials aimed at improved survival have
been initiated ([6] and NCT03525288). Overall, false
[68Ga]Ga-PSMA-11 PET interpretations by trained physicians
occur in less than 10% of cases [4]. However, physicians need
to be informed about potential pitfalls in order to improve qual-
ity of their interpretations. Here we report details for [68Ga]Ga-
PSMA-11 PET findings that were discordant with the reference
standard in a recently published prospective trial [4]. We aim to
characterize sources of [68Ga]Ga-PSMA-11 PET misinterpre-
tation and potential limitations of the reference standard.
Material and methods
Enrollment criteria, imaging, and lesion validation protocols
have been reported previously [4]. In brief, inclusion criteria
were histopathology proven prostate adenocarcinoma and bio-
chemical recurrence. Biochemical recurrence was defined as
PSA ≥ 0.2 ng/mL more than 6 weeks after prostatectomy or
PSA ≥ 2 ng/mL rises above nadir following radiation therapy
(ASTRO-Phoenix consensus definition). Patients were en-
rolled irrespective of prior imaging findings.
Patients underwent PET/CT (n = 443, 70%) or PET/MRI
(n = 192, 30%) based on availability and contraindications.
Imaging parameters are given in Supplemental Table 1.
Interpretation and validation criteria were reported previ-
ously [4]. In brief, cases were assigned to nine off-site readers
(three readers per dataset) that were not involved in study
design and data acquisition. All readers underwent training
based on a previous dataset [7]. Readers were provided whole
body PET (attenuation corrected and non-corrected), whole
body post-contrast CT, or whole-body post-gadolinium T1
and pelvic T2 MRI. Most recent PSA level and type of prima-
ry therapy (prostatectomy versus radiation therapy) were
disclosed; however, readers were blind to all other informa-
tion. The presence of prostate cancer (positive versus nega-
tive) as well as visual PSMA expression was recorded.
Consensus was determined by majority vote.
PET positive findings were validated as true or false posi-
tive. Regions, negative on [68Ga]Ga-PSMA-11 PET, but with
subsequently confirmed prostate cancer by histopathology,
were considered false negative. True negative was not de-
fined. Descriptive statistics are provided.
Results
Characteristics of the entire cohort have been reported previ-
ously [4]. Details for false positive findings on a region basis
are given in Table 1. Summary images are shown in
Supplemental Figure 1. Consensus reads were false positive
in 20 regions of 17/217 (8%) patients with lesion validation.
Eleven of 20 (55%) false positive cases were documented for
suspected relapse in the prostate after radiotherapy. These 11
cases had lesions within the prostate that demonstrated resid-
ual PSMA expression months to years after radiotherapy de-
spite benign tissue or cell appearance consistent with success-
ful treatment response. Examples of residual PSMA expres-
sion are illustrated in Figs. 1 and 2. Of note, consensus reads
were true positive in 36 of 47 (77%) cases with suspected
relapse in the prostate post radiotherapy.
In two cases, uptake in the prostate bed after prostatectomy
led to false positive PET interpretation. For one of the two
patients, subsequent surgery confirmed the presence of an
inter-sphincteric abscess. In four cases, small pelvic or retro-
peritoneal nodes were associated with false positive findings.
Uptake in the lung led to false positive interpretation for pros-
tate cancer in 2 cases (1 patient with lung cancer and 1 patient
with bronchogenic cyst; Fig. 3). Visual PET uptake was inter-
mediate to low in 15 (75%) and high in 5 of 20 (25%) false
positive lesions according to PROMISE [8].
Eight cases of false negative interpretation were document-
ed. Cause of the false negative interpretation was adjacent
urine/bladder/rectum uptake in 4 of 8 (50%) and small size
of metastases in 3 of 8 (38%). Of note, no scatter artifact from
high urine activity was noted. Details for false negative find-
ings on a region basis are given in Supplemental Table 2.
Summary images are shown in Supplemental Figure 2. One
lung lesion demonstrated no uptake on PET/CT and was false
negative potentially due to partial volume effect and/or respi-
ratory movement. One bone biopsy was performed, which
confirmed prostate cancer (true positive).
Discussion
Our recent prospective trial reports 84 to 92% [68Ga]Ga-
PSMA-11 PET positive predictive value and 75% overall
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detection rate for localization of recurrent prostate cancer [4].
[68Ga]Ga-PSMA-11 PET is an imaging test for PSMA,
expressed at high level by most prostate cancer lesions.
Biodistribution of the radiotracer and PSMA expression level
of prostate cancer and normal tissues may lead to false clinical
interpretations. Here we present details for false PET interpre-
tations of the blinded consensus reads.
[68Ga]Ga-PSMA-11 PET at biochemical recurrence result-
ed in less than 10% false positive interpretations. About two-
thirds of all documented false positive interpretations occurred
in the context of suspected recurrence in the prostate post-
radiotherapy. Following radiation therapy, cancer and prostate
tissue undergo considerable molecular and histologic change
over time. Effects vary with dose and duration of therapy,
interval from onset, and addition of systemic treatment [9].
Prostate cancer regresses slowly, and complete histologic res-
olution may take several years [10, 11]. Typically, post-
radiotherapy biopsy results are rated positive for prostate can-
cer (accompanied with Gleason Scoring), severe treatment
effect, or negative for prostate cancer [12]. In a previous report
severe treatment effect and negative biopsy were associated
with similar risk for biochemical failure, distant metastases,
and cause specific mortality [13]. Risk for both categories was
significantly lower when compared with positive biopsy [13].
Residual adenocarcinoma with severe treatment effect was
seen on biopsy for 3 of 11 false positive post-radiotherapy
prostate specimens in our trial. Despite severe treatment effect
immunohistochemistry demonstrated high PSMA expression
of tumor cells and adjacent glands (Figs. 1 and 2). It was
shown previously that molecular features such as PSA expres-
sion or molecular weight keratin can be retained in adenocar-
cinoma despite marked response to radiation therapy [10].
Rising PSA may originate from lesions outside the pros-
tate, not detected by [68Ga]Ga-PSMA-11 PET. However,
residual prostate cancer with severe treatment effect, even
without conversion into progressive disease, is another pos-
sible source of PSA [10]. In observational trials, disease-
free survival in patients with residual prostate cancer with
severe treatment effect versus negative biopsy was similar
[13, 14]. This suggests that PSMA expression within the
irradiated prostate, detected by PET, does not necessarily
indicate active disease. However, clinical significance of
Fig. 1 70-year-old man post-radiotherapy 10 years prior, who demon-
strates focal [68Ga]Ga-PSMA-11 uptake in the right medial prostate (a,
circle; b) (PSA 2.6 ng/mL, CT FP 3). Trans-anal ultrasound guided core
needle biopsy demonstrated no evidence of viable tumor. The specimen
in the region of the focal uptake (SUVmax 9.1) demonstrated marked
radiation changes in residual benign glands (d, dotted circle), cancer with
treatment effect including balloon cells (e, black arrows), and cells with
marked PSMA expression (c and f, black arrows). Adjacent benign
glands did not demonstrate PSMA expression (c, black arrow heads)
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PSMA-expressing remnants post-radiotherapy has yet to be
assessed in the setting of biochemical failure. Of note, PET
consensus reads were true positive in 36 of 47 (77%) cases
with suspected relapse in the prostate post radiotherapy.
In general, patients in a BCR setting are at particular
risk for early disease progression, providing a rationale
for physicians to offer salvage treatment after primary
radiotherapy [15]. However, in previous studies post-
radiotherapy residual cancer with severe treatment effect
was not associated with progression or poor survival [13,
14]. In patients with isolated and late prostate recurrence,
observation remains a favorable management option, and
potentially morbid salvage therapy should be considered
with caution in the absence of histopathologic verification
or extra-prostatic progression [16].
Accuracy of biopsy for the diagnosis of prostate cancer is
somewhat limited as demonstrated by previously reported dis-
cordance with whole-gland pathology [17]. Sample interpre-
tation, which requires accurate separation of carcinoma from
its many mimics and discrimination of treatment effects in
normal tissue from recurrent or persistent carcinoma, is diffi-
cult [9]. With the availability of highly sensitive [68Ga]Ga-
PSMA-11 PET imaging, we anticipate that the frequency of
imaging detected potential local failures after prostate radio-
therapy will increase. This in turn will increase the number of
post-radiation biopsies requiring careful pathologic evaluation
prior to initiation of salvage therapy.
[68Ga]Ga-PSMA-11 PET/MRI interpretation resulted in two
false positive lung findings. One patient demonstrated focal
tracer uptake of right upper lobe lung cancer. Focal uptake
was interpreted as prostate cancer lung metastasis by all three
readers. This interpretation accounts for a false positive finding
with respect to prostate cancer detection; however, subsequent
diagnosis of lung cancer considerably altered oncologic man-
agement. Another patient demonstrated focal uptake in a bron-
chogenic cyst with prominent peribronchial glands (Fig. 3). Of
note, peribronchial glands are similar to salivary gland epithe-
lium with known high physiologic radioligand accumulation.
Similar mechanism in peribronchial glands may explain focal
[68Ga]Ga-PSMA-11 uptake here.
In three cases, sub-centimeter nodes demonstrated in-
tense focal uptake on PET; however, lymph node size did
not change significantly under systemic therapy to confirm
nodal involvement in accordance with reference standard
criteria. Intrinsic limitations of validation criteria, especial-
ly limited size change in small lesions, have been discussed
previously [4]. On the other hand, [68Ga]Ga-PSMA-11 PET
reaches detection limits for small nodal metastases, espe-
cially close to areas of high physiologic uptake. In line with
previous reports, false negative findings occurred for small
Fig. 2 74-year-old man post-radiotherapy performed 10 months prior
with biochemical recurrence who had focal uptake on the right peripheral
zone of the prostate (a, circle) (PSA 7.2 ng/mL, MRI FP 7). Neither T2
weighted imaging (b, arrow), dynamic contrast enhanced (DCE) imaging
or diffusion weighted imaging demonstrated a focal lesion to correlate
with the focal uptake (SUVmax 12.5) seen on [
68Ga]Ga-PSMA-11. Trans-
anal ultrasound guided core needle biopsy was obtained from the region
of uptake. Pathology demonstrates tumor cells with significant treatment
effect (c) and marked PSMA expression (d). There was no evidence of
PSMA expression in vasculature
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size metastases or adjacent bladder/urine uptake [18, 19].
Additional CT urography demonstrated value in identifica-
tion of [68Ga]Ga-PSMA-11 PET findings adjacent to the
urinary system [20].
Conclusion
A prospective multi-center trial with blinded reads and lesion
validation revealed false positive [68Ga]Ga-PSMA-11 PET in
20 regions of 17/217 (8%) patients [4]. Faint to moderate
[68Ga]Ga-PSMA-11 uptake in the prostate post-radiotherapy
was a major source of false positive findings. Uptake was
noted in PSMA-expressing benign tissue or tumor remnants
with successful treatment response by histopathology.
Previous studies report limited prognostic relevance of these
remnants underlining the importance of additional pathologic
evaluation [13, 14]. Other pitfalls were inflammation for false
positive, and urine activity or small size metastases for false
negative [68Ga]Ga-PSMA-11 PET.
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